Literature DB >> 3084646

Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine. III. Correlation of resistance with induction of activated larvacidal macrophages.

S L James.   

Abstract

Mice protected against Schistosoma mansoni infection by intradermal (i.d.) immunization with nonliving larval or adult worm antigens plus bacterial adjuvant developed 24-hr skin test responsiveness to schistosome antigens with the histologic features of delayed hypersensitivity. Intraperitoneal antigen injection elicited a mononuclear cell-enriched exudative population containing macrophages activated for direct cytotoxicity against schistosomula and tumor cell targets. This was likely to be due to in vivo exposure to macrophage-activating lymphokines, since these cells were unresponsive to further lymphokine stimulation in vitro and splenocytes from immunized mice reacted to specific in vitro antigen challenge by production of lymphokines capable of conferring larvacidal activity upon control macrophages. In contrast, mice treated with schistosome antigens by i.v. injection, which were not protected against challenge infection, failed to develop delayed hypersensitivity or activated macrophages in response to specific antigen challenge in vivo, and the titers of macrophage-activating lymphokine produced by in vitro antigen-stimulated splenocytes from these mice were threefold to fourfold lower than those produced by cells from animals immunized by the i.d. route. Thus, sensitization for cell-mediated immune responses including lymphokine production and macrophage activation correlated with induction of resistance to S. mansoni in this model of vaccination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084646

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Schistosome vaccines.

Authors:  D W Taylor
Journal:  Experientia       Date:  1991-02-15

2.  Effects of inhibitors of tumoricidal activity upon schistosomulum killing by activated macrophages.

Authors:  S L James; J A Glaven
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

3.  Genetic association of defects in macrophage larvicidal activity and vaccine-induced resistance to Schistosoma mansoni in P strain mice.

Authors:  S L James; R Correa-Oliveira; A Sher; L A Medvitz; R D McCall
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

4.  Enhanced interleukin-12 and CD40 ligand activities but reduced Staphylococcus aureus Cowan 1-induced responses suggest a generalized and progressively impaired type 1 cytokine pattern for human schistosomiasis.

Authors:  Silvia M L Montenegro; Frederico G C Abath; Ana Lúcia C Domingues; Wlademir G Melo; Clarice N L Morais; Eridan M Coutinho; Siddhartha Mahanty; Thomas A Wynn
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

5.  Macrophage activation as an immune correlate to protective immunity against schistosomiasis in mice immunized with an irradiated, cryopreserved live vaccine.

Authors:  F A Lewis; J Winestock; S L James
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

6.  Schistosomiasis and in vitro transdifferentiation of murine peritoneal macrophages into fibroblastic cells.

Authors:  M Godoy; M Geuskens; E A Van Marck; R Borojevic; P Van Gansen
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

7.  Effect of cholera toxin on vaccine-induced immunity and infection in murine schistosomiasis mansoni.

Authors:  A A Akhiani; L A Nilsson; O Ouchterlony
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

8.  Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen.

Authors:  E J Pearce; S L James; S Hieny; D E Lanar; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Measurement of gamma-interferon in culture supernatants of antigen-stimulated lymphocytes from patients with Schistosoma mansoni infections by a reverse passive haemagglutination assay.

Authors:  A E Butterworth; A Wilson; B A Richardson; J Harris; R K Gachuhi; D Senior; R R Coombs
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.